Alpine Immune Sciences Announces Pricing of $150 Million Public Offering
07 November 2023 - 1:41PM
Business Wire
Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a clinical-stage
immunotherapy company focused on developing innovative treatments
for autoimmune and inflammatory diseases, today announced the
pricing of its underwritten public offering of 8,800,000 shares of
its common stock and, in lieu of shares of common stock to certain
investors, pre-funded warrants to purchase up to 3,200,000 shares
of its common stock, pursuant to its existing shelf registration
statement. The shares of common stock are being offered at a public
offering price of $12.50 per share and the pre-funded warrants are
being offered at a price of $12.499 per pre-funded warrant, which
equals the public offering price per share of the common stock less
the $0.001 exercise price per share of each pre-funded warrant. The
gross proceeds to Alpine from the offering, before deducting
underwriting discounts and commissions and other offering expenses
payable by Alpine, are expected to be approximately $150.0 million.
In addition, Alpine has granted the underwriters of the offering an
option for a period of 30 days to purchase up to an additional
1,800,000 shares of common stock at the public offering price, less
the underwriting discounts and commissions. All shares of common
stock to be sold in the offering are being sold by Alpine. The
offering is expected to close on or about November 9, 2023, subject
to customary closing conditions.
Morgan Stanley, TD Cowen and Leerink Partners are acting as
joint book-running managers for the proposed public offering. RBC
Capital Markets is acting as a bookrunner and Oppenheimer & Co.
and H.C. Wainwright & Co. are acting as co-lead managers for
the proposed public offering.
A shelf registration statement relating to the securities
offered in the public offering described above was filed with the
Securities and Exchange Commission (SEC) on April 28, 2023 and
declared effective by the SEC on May 9, 2023. The offering is being
made only by means of a written prospectus and prospectus
supplement that form a part of the registration statement. A
preliminary prospectus supplement and accompanying prospectus
relating to the offering have been filed with the SEC and are
available on the SEC’s website at www.sec.gov. A final prospectus
supplement and accompanying prospectus will be filed with the SEC.
When available, copies of the final prospectus supplement and the
accompanying prospectus may also be obtained by contacting Morgan
Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick
Street, 2nd Floor, New York, New York 10014, by telephone:
1-866-718-1649, or by email at prospectus@morganstanley.com; Cowen
and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by
telephone at (833) 297-2926, or by email at
Prospectus_ECM@cowen.com; Leerink Partners LLC, Attention:
Syndicate Department, 53 State Street, 40th Floor, Boston, MA
02109, by telephone at (800) 808-7525, ext. 6105, or by email at
syndicate@leerink.com; RBC Capital Markets, by mail at RBC Capital
Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street,
8th Floor, New York, NY 10281 or by telephone at (877) 822-4089, or
by email at equityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor
shall there be any sale of the securities being offered in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are not based on historical fact and include statements
regarding the anticipated closing of the public offering. These
forward-looking statements are based on current assumptions that
involve risks, uncertainties and other factors that may cause the
actual results, events or developments to be materially different
from those expressed or implied by such forward-looking statements.
These risks and uncertainties, many of which are beyond our
control, include, but are not limited to, uncertainties related to
market conditions and the completion of the public offering on the
anticipated terms or at all, as well as the other risks identified
in our filings with the SEC. These forward-looking statements speak
only as of the date hereof and we assume no obligation to update
these forward-looking statements, and readers are cautioned not to
place undue reliance on such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231106758126/en/
Media and Investor Relations
Contact: Temre Johnson Alpine Immune Sciences, Inc.
ir@alpineimmunesciences.com media@alpineimmunsciences.com
Alpine Immune Sciences (NASDAQ:ALPN)
Historical Stock Chart
From Apr 2024 to May 2024
Alpine Immune Sciences (NASDAQ:ALPN)
Historical Stock Chart
From May 2023 to May 2024